Tangram Therapeutics submitted a clinical trial application to the U.K. MHRA to initiate a Phase I/II study of TGM‑312 for metabolic dysfunction‑associated steatohepatitis (MASH). The CTA filing signals Tangram’s transition from preclinical development into first‑in‑human testing for a metabolic liver program. The company expects the trial to evaluate safety, pharmacodynamics and biomarkers of liver inflammation and fibrosis as it positions TGM‑312 for an indication with significant unmet need.